Clinical

The findings, say the researchers, provide a basis for future exploration of the activity of energy metabolism pathways in clonal plasma cells of patients newly diagnosed with the disease.

According to the researchers of this new study, the biomarker may have potential for use with clinical scores in treatment decisions or in clinical trials that focus on hidradenitis suppurativa (HS).

The researchers highlighted a need for the detection of more relevant markers and guidance on how to treat adverse events (AEs), the types and severity of which vary based on disease type.

In this study, outcomes were investigated among a cohort of patients with heart failure with reduced ejection fraction (HFrEF) who participated in a cardiac rehabilitation program post hospital discharge after they survived acute onset of HFrEF.

In this new study, researchers wrote of the implications that detailed an association between asthma and exposure to particulate matter less than or equal to 2.5 mcm.

New global data put the COVID-19 death toll at just under 15 million; the FDA issues a warning limiting use of Johnson & Johnson vaccine; US sees increase in aggressive uterine cancer cases.

Payer considerations regarding unintended pregnancy is discussed by Maria Lopes, MD, MS, and Kevin Stephens Sr., MD, JD.

Ayman Al-Hendy, MD, PhD identifies risk factors for development of US and endometriosis.

Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, addresses the placebo effect seen in clinical trials of chronic cough treatment.

This approval of trastuzumab deruxtecan (Enhertu) follows the March release of data from the DESTINY-Breast03 trial on the anti-HER2 monoclonal antibody, also a HER2-directed antibody-drug conjugate, which indicated superior outcomes vs trastuzumab emtansine.

Investigators found 6 genes associated with cancer-associated fibroblasts that appear to correlate with response to anti-PD-1 immunotherapy.

Drs Steven Levine, Patricia Ares-Romero, Samuel Nordberg, Martin Rosenzweig, and Carrie Jardine share insight on the future treatment landscape for TRD.

Dr Martin Rosenzweig discusses the importance of data collection to improve patient care in TRD as well as alternative payment models.

In patients with liver involvement, intrahepatic cholangiocarcinoma was a common diagnosis among some patients with cancer of unknown primary (CUP).

Limited evidence from a literature review suggests that co-pay assistance was associated with improved treatment persistence/adherence across various diseases, with indirect evidence suggesting improvements in clinical outcomes.

Medication dose captures modification of hypertension treatment intensity more precisely than medication count, and this measure should be preferred in studies that aim to improve hypertension management.

The proportion of colonoscopies performed for postpolypectomy surveillance has increased significantly, particularly among older patients with limited life expectancy, raising concern for possible overuse.

Among patients with rheumatoid arthritis (RA) in clinical remission, patient-physician discordance when assessing disease activity may be associated with the inability to achieve remission.

Dr Eliot Brinton elaborates on unmet needs in lipid management and how they can be remedied.

Ian Riddock, MD, and Leandro N. Slipczuk, MD, PhD, discuss the importance of LDL-C management as part of the discharge plan for patients, as well as ensuring continuity of care from the inpatient to outpatient setting.

Of the 5800 patients included in study, 20% were Black, which the researchers say adequately represents disease incidence among the population.

Among the fewer than half of patients with cancer who received opioid fills, a relatively small proportion (2.5%) had potentially problematic opioid use.

Although classic methods of risk stratification still hold value, the authors said genetic analysis holds significant promise.

The study showed that introducing the TLR7 variant in an animal model led to the development of autoimmune symptoms and potential development of systemic lupus erythematosus (SLE).

Fidaxomicin, now commonly used to treat Clostridioides difficile infection, selectively targets the bacterium while sparing crucial gut commensals that protect against colonization. However, knowledge gaps in the molecular basis of its narrow-spectrum activity remain.